• Confirmation of Directorate Change

    Read more
  • Directorate Change

    Read more
  • Zelasudil granted FDA Orphan Drug Designation

    Read more
  • Directorate Change

    Read more
  • Redx to Present at Jefferies Global Healthcare Conference in New York

    Read more
  • Interim Results for the Six Months Ended 31 March 2023

    Read more
  • Redx Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

    Read more
  • Notice of Interim Results

    Read more
  • Redx to Present Additional Preclinical Efficacy of RXC007 and DDR1/2 Inhibitors in Cancer-Associated-Fibrosis Models at The Resistant Tumour Microenvironment, Keystone Symposia

    Read more
  • Redx Announces RXC004 Topline Data From a Phase 2 Monotherapy Module

    Read more